Should I Buy TECH? TECH 2026 Analysis

Should You Buy Bio-Techne Corp (TECH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

63.980

1 Day change

-2.41%

52 Week Range

79.280

Analysis Updated At

2026/01/26

Bio-Techne Corp (TECH) is not a strong buy for a beginner, long-term investor at the moment. While the stock shows some positive financial performance trends, the lack of strong technical signals, mixed analyst ratings, and significant insider and hedge fund selling suggest caution. The investor should consider waiting for clearer positive catalysts or a more favorable entry point.

Technical Analysis

The technical indicators are mixed. The MACD is positive but contracting, RSI is neutral at 52.528, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 68.17, with resistance at 71.322 and support at 65.019. However, no strong upward momentum is evident.

Options Data

Bullish

Open Interest Put-Call Ratio

Bullish

Option Volume Put-Call Ratio

Technical Summary

Sell

Buy

Positive Catalysts

The company's Q1 financials show a 13.65% YoY increase in net income, a 14.29% YoY increase in EPS, and a 2.14% YoY improvement in gross margin. Additionally, the stock has a 70% chance to rise by 5.75% in the next month based on historical candlestick patterns.

Neutral/Negative Catalysts

Hedge funds and insiders are heavily selling, with hedge fund selling up 5004.01% and insider selling up 2911.08%. Analyst ratings are mixed, with recent downgrades and price target reductions. No recent news or significant positive sentiment is evident.

Financial Performance

In Q1 2026, Bio-Techne's revenue dropped by 1.00% YoY to $286.56M, but net income increased by 13.65% YoY to $38.18M. EPS rose by 14.29% YoY to 0.24, and gross margin improved by 2.14% YoY to 66.37%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analyst ratings are mixed. Evercore ISI recently downgraded the stock to In Line with a price target of $62 (down from $68). Deutsche Bank raised its price target to $72, citing acquisition benefits. UBS maintains a Buy rating with a $70 target, while Baird lowered its target to $61 with a Neutral rating. Overall, there is no strong consensus for a buy.

9 Analyst Rating

Wall Street analysts forecast TECH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TECH is 66.14 USD with a low forecast of 60 USD and a high forecast of 72 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

3 Hold

0 Sell

Moderate Buy

Current: 65.560

Low

Averages

66.14

High

Current: 65.560

Low

Averages

66.14

High

Evercore ISI

Outperform -> In Line

downgrade

$68 -> $62

AI Analysis

2026-01-05

Reason

Evercore ISI

Price Target

$68 -> $62

AI Analysis

2026-01-05

downgrade

Outperform -> In Line

Reason

Evercore ISI downgraded Bio-Techne to In Line from Outperform with a price target of $62, down from $68.

Deutsche Bank

Justin Bowers

Buy

maintain

$66 -> $72

2025-12-12

Reason

Deutsche Bank

Justin Bowers

Price Target

$66 -> $72

2025-12-12

maintain

Buy

Reason

Deutsche Bank analyst Justin Bowers raised the firm's price target on Bio-Techne to $72 from $66 and keeps a Buy rating on the shares. The firm cites accretion prospects of Bio-Techne's acquisition of Wilson Wolf for the target increase.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TECH

Unlock Now

TECH Should I Buy

TECH Should I Buy

Should You Buy Bio-Techne Corp (TECH) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch